Abhishek Kumar Mishra

Dr. Abhishek Kumar Mishra

Masonic Medical Research Laboratory, Utica, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2018 in Veterinary World
Verified
Journal Article
Open access
AMAbhishek Kumar Mishra
Abhishek Kumar Mishra
AKAkshay Kumar
Akshay Kumar
Dilip Kumar SwainDilip Kumar Swain
Dilip Kumar Swain
SYSarvajeet - Yadav
Sarvajeet - Yadav
RNRajesh Nigam
Rajesh Nigam
This mini-review discusses the probable mechanisms involved in pH regulation in sperm cells and how pH is involved in regulation of various sperm functions

27 April 2022 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
AMAbhishek Mahajan
Abhishek Mahajan
PSPratishtha Sharma
Pratishtha Sharma
AMAbhishek Kumar Mishra
Abhishek Kumar Mishra
SGShashikant Gupta
Shashikant Gupta
SYSarvajeet Yadav
Sarvajeet Yadav
Dilip Kumar SwainDilip Kumar Swain
Dilip Kumar Swain

23 November 2018 in Veterinary World
Verified
Journal Article
Open access
AKAkshay Kumar
Akshay Kumar
AMAbhishek Kumar Mishra
Abhishek Kumar Mishra
Dilip Kumar SwainDilip Kumar Swain
Dilip Kumar Swain
VSVijay Singh
Vijay Singh
SYSarvajeet - Yadav
Sarvajeet - Yadav
ASAtul Saxena
Atul Saxena
Some insights into the action of TRP channels in regulating sperm fertility competence through both calcium-dependent and calcium-independent mechanisms

11 February 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MTMahtab Tavasoli
Mahtab Tavasoli
TFTiam Feridooni
Tiam Feridooni
HFHirad Feridooni
Hirad Feridooni
SSStanislav Sokolenko
Stanislav Sokolenko
AMAbhishek Kumar Mishra
Abhishek Kumar Mishra
CMChristopher R. McMaster
Christopher R. McMaster
The CHKB gene encodes choline kinase β, which catalyzes the first step in the biosynthetic pathway for the major phospholipid phosphatidylcholine. Homozygous loss-of-function variants in human CHKB are associated with a congenital muscular dystrophy. Dilated cardiomyopathy is present in some CHKB patients and can cause heart failure and death. Mechanisms underlying a cardiac phenotype due to decreased CHKB levels are not well characterized. We determined that there is cardiac hypertrophy in Chkb−/− mice along with a decrease in left ventricle size, internal diameter, and stroke volume compared with wildtype and Chkb+/− mice. Unlike wildtype mice, 60% of the Chkb+/− and all Chkb−/− mice tested displayed arrhythmic events when challenged with isoproterenol. Lipidomic analysis revealed that the major change in lipid level in Chkb+/− and Chkb−/− hearts was an increase in the arrhythmogenic lipid acylcarnitine. An increase in acylcarnitine level is also associated with a defect in the ability of mitochondria to use fatty acids for energy and we observed that mitochondria from Chkb−/− hearts had abnormal cristae and inefficient electron transport chain activity. Atrial natriuretic peptide (ANP) is a hormone produced by the heart that protects against the development of heart failure including ventricular conduction defects. We determined that there was a decrease in expression of ANP, its receptor NPRA, as well as ventricular conduction system markers in Chkb+/− and Chkb−/− mice.

14 June 2022 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
AMAbhishek Kumar Mishra
Abhishek Kumar Mishra
Kishore B. S. PasumarthiKishore B. S. Pasumarthi
Kishore B. S. Pasumarthi
Congenital heart defects (CHD) are the most common type of birth defects. Several human case studies and genetically altered animal models have identified abnormalities in the development of ventricular conduction system (VCS) in the heart. While cell-based therapies hold promise for treating CHDs, translational efforts are limited by the lack of suitable in vitro models for feasibility and safety studies. A better understanding of cell differentiation pathways can lead to development of cell-based therapies for individuals living with CHD/VCS disorders. Here, we describe a new and reproducible 3-D cell culture method for studying cardiac cell lineage differentiation in vitro. We used primary ventricular cells isolated from embryonic day 11.5 (E11.5) mouse embryos, which can differentiate into multiple cardiac cell types including VCS cells. We compared 3-D cultures with three types of basement membrane extracts (BME) for their abilities to support E11.5 ventricular cell differentiation. In addition, the effects of atrial natriuretic peptide (ANP) and an inhibitor for its high affinity receptor were tested on cell differentiation in 3-D cultures. Following the cell culture, protocols for immunofluorescence imaging, cell extraction and protein isolation from the 3-D culture matrix and in-cell western methods are described. Further, these approaches can be used to study the effects of various ligands and genetic interventions on VCS cell development. We propose that these methodologies may also be extended for differentiation studies using other sources of stem cells such as induced pluripotent stem cells.